mathom/ct_dataset huggingface dataset:
Provide description for trial id: NCT05680662  
 breast cancer is the most common cancer in women. With more than 1 in 10 new cancer diagnoses each year, It is the second most frequent cancer-related death among women worldwide. Breast cancer develops slowly, and the majority of cases are found through routine screening.

breast cancer-causing deaths among women all over the world and increased in the last few years even though the treatment is advanced like immunotherapy chemotherapy by yet no treatment for triple-negative breast cancer zinc and competition between znt1 and zip6,10 at breast cancer cells. Is zinc ionophore like quercetin and EGCG has a role, In a novel experimental study zinc is a trace metal that has many roles in cells, enzymatic activity, and gene regulations, and also for the integrity of DNA.

Zinc transporters (zinc related -proteins such as ZIPs, and ZnTs are affected by triggers factors like cytokines and growth factors.

There are two large families of zinc transporters like ZIPs ( 14 members) and ZnTs family (10 members), ZIPS family cause an influx of zinc from the extracellular to the cytoplasm and also from intracellular organelles like endoplasmic reticulum or Golgi or mitochondria in contrast to ZnTs which cause an influx of zinc from the cytoplasm to intracellular organelles. ( lower cytoplasmic zinc) (1) Breast cancer deaths occurred from metastasis; Catalytic enzymes called proteases like cathepsin L are frequently overexpressed in aggressive cancers. Breast tumor metastatic potential is correlated with macrophage presence. These macrophages associated with tumors frequently adopt an M2-like pro-tumorigenic phenotype, which results in the production of growth hormones and proteases, notably the lysosomal protease cathepsin L. Because cathepsin L is commonly released by breast cancer cells and aids in tumor invasion, metastasis, and angiogenesis. It is expected that cathepsin L secretion by both tumor-associated macrophages and neoplastic cells would promote the metastatic phenotype because cathepsin L is widely produced by breast cancer cells and helps with tumor invasion, metastasis, and angiogenesis. (2) this study target new mechanisms and achieves the best management as some types of cancer breast like triple-negative breast cancer (TNBC) no definite treatment so we target the following pathways and epigenetic processes by these adjuvant compounds which have a promising role in the immunity like EGCG, Quercetin, Zinc, Metformin so our team will discuss novel methods to achieve the best efficacy from chemotherapy
Trial Id: Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40 Recruitment Status: Unknown status Trail description: This study aimed to validate the diagnostic ability of the CDT (cancer detection technology) software to detect breast cancer among women population. Inclusion Criteria: Inclusion Criteria for Breast Cancer Patients for Experimental Group:

Patient is over the age of 40.
Patient is willing to participate as evidenced by signing the written informed consent form.
Patient referred to the Department of Oncology/ Surgery for operative treatment of breast cancer with previously detected disease. Positive conventional tests finding can include (but not limited to) the record of screening or diagnostic mammography, blood oncomarkers, breast ultrasound, breast CT, biopsy.
Non-treated patients (w/o previous chemotherapy, hormonal drugs and radiotherapy).
Patient without other cancer locations

Inclusion Criteria for Presumably Healthy Subjects for Control Group:

Subjects over the age of 40.
Subjects who are willing to participate as evidenced by signing the written informed consent form.
Subjects who are presumably healthy and without breast pathologies' symptoms and family history of breast cancer, i.e., breast disease (except history of functional breast problems, e.g., mastitis within lactation period) has been ruled out based on physician anamnesis
Subjects with negative results of screening mammography.
Subjects without taking of any hormonal medicines Exclusion Criteria: Subjects with any known cancer in other internal organs or systems.
Subjects with high fever presentation (more than 38.5).
Subjects with known breast disease undergoing treatment for the disease.
Pregnant or lactating women
Provide inclusion criteria for trial id: NCT01043055  
 Inclusion Criteria for Breast Cancer Patients for Experimental Group:

Patient is over the age of 40.
Patient is willing to participate as evidenced by signing the written informed consent form.
Patient referred to the Department of Oncology/ Surgery for operative treatment of breast cancer with previously detected disease. Positive conventional tests finding can include (but not limited to) the record of screening or diagnostic mammography, blood oncomarkers, breast ultrasound, breast CT, biopsy.
Non-treated patients (w/o previous chemotherapy, hormonal drugs and radiotherapy).
Patient without other cancer locations

Inclusion Criteria for Presumably Healthy Subjects for Control Group:

Subjects over the age of 40.
Subjects who are willing to participate as evidenced by signing the written informed consent form.
Subjects who are presumably healthy and without breast pathologies' symptoms and family history of breast cancer, i.e., breast disease (except history of functional breast problems, e.g., mastitis within lactation period) has been ruled out based on physician anamnesis
Subjects with negative results of screening mammography.
Subjects without taking of any hormonal medicines
Trial Id: Oncoliq: Test for Early Breast Cancer Detection. Recruitment Status: Recruiting Trail description: Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs.

To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity.

Currently it is been setting up a "pilot test" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection. Inclusion Criteria: Women patients performing gynecological control
Between 50-70 years old
Without personal history of oncological disease
Informed consent signed Exclusion Criteria: Patients who don´t meet the inclusion criteria.
Active infection with SARS-CoV-2 (COVID-19).
Provide description for trial id: NCT04906330  
 Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs.

To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity.

Currently it is been setting up a "pilot test" for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection.
Trial Id: Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT Recruitment Status: Completed Trail description: The purpose of this study is to elucidate the value of dual-time-point PET/CT in the recurrence of breast cancer and to determine whether the method is better than the modalities used in the standard work up.

150 patients with suspected breast cancer recurrence will be included. All patients will undergo dual-time-point PET/CT, CT of thorax and upper abdomen and bone scintigraphy. After completion of the examinations the early and the late PET/CT scan will be compared with each other, the diagnostic CT-scan and the bone scintigraphy. A verification of suspicious findings will be done by biopsy, if the area is accessible. If a biopsy cannot be obtained, the presence of recurrence will be verified with additional imaging follow-up to ensure the highest possible confidence. Sensitivity, specificity, accuracy, negative and positive predictive value (NPV/PPV) will be calculated for each modality (incl. early and late PET/CT). Inclusion Criteria: Clinical suspected recurrence of breast cancer
Blood glucose level less than 8,0 mmol/L Exclusion Criteria: Disqualified patients
Other malignancies
< 18 years
< 50 kg
> 90 kg
Pregnant or lactating
Patients with permanent address outside of the Region of Southern Denmark
Estimated inability to collaborate
Provide description for trial id: NCT01552655  
 The purpose of this study is to elucidate the value of dual-time-point PET/CT in the recurrence of breast cancer and to determine whether the method is better than the modalities used in the standard work up.

150 patients with suspected breast cancer recurrence will be included. All patients will undergo dual-time-point PET/CT, CT of thorax and upper abdomen and bone scintigraphy. After completion of the examinations the early and the late PET/CT scan will be compared with each other, the diagnostic CT-scan and the bone scintigraphy. A verification of suspicious findings will be done by biopsy, if the area is accessible. If a biopsy cannot be obtained, the presence of recurrence will be verified with additional imaging follow-up to ensure the highest possible confidence. Sensitivity, specificity, accuracy, negative and positive predictive value (NPV/PPV) will be calculated for each modality (incl. early and late PET/CT).
Trial Id: PERSONAL - Sleep In Breast Cancer Recruitment Status: Completed Trail description: Sleep is essential for human function, immunity, and well-being. In the general population, sleep disturbance and insomnia cause significant health problems and impact on the quality of life of many individuals. The incidence of insomnia in cancer patients is disproportionality higher, with breast cancer patients experiencing prevalence rates ranging from 19% to 69%. The impact of insomnia on cancer patients' lives can be significant and is associated with depression, cancer-related fatigue, increased pain, reduced quality of life, decreased immunity, disease progression, and survival. To date, breast cancer studies show large variation in reported insomnia prevalence rates, and the severity of sleep complaints in these patients have been difficult to assess. Thus, these issues require further investigation using standardised and validated measures.

In this observational study, we aim to investigate the prevalence and severity of insomnia in a cohort of breast cancer patients at the Christie Hospital using the Insomnia Severity Index (ISI), a validated measure for insomnia. This study will consist of two stages. In Stage 1, patients aged 18 and over, who provide informed consent and have a diagnosis of Stage I, II or III breast cancer in the previous 12 months will be asked to complete the validated ISI. Using the ISI, participants identified as having sleeping difficulties and/or insomnia will be invited to Stage 2 of the study. In this stage, participants will be asked to track their sleep each morning for 3 weeks using a digital sleep diary downloaded onto their own smartphone. They will also be asked to complete a series of questionnaires gathering information regarding their quality of life, well-being, and health. This research will provide a better understanding of sleeping patterns, sleeping difficulties and insomnia in patients with breast cancer, and in the long-term, help us design better treatments for patients with sleeping problems. Inclusion Criteria: None Exclusion Criteria: None
Provide description for trial id: NCT05093426  
 Sleep is essential for human function, immunity, and well-being. In the general population, sleep disturbance and insomnia cause significant health problems and impact on the quality of life of many individuals. The incidence of insomnia in cancer patients is disproportionality higher, with breast cancer patients experiencing prevalence rates ranging from 19% to 69%. The impact of insomnia on cancer patients' lives can be significant and is associated with depression, cancer-related fatigue, increased pain, reduced quality of life, decreased immunity, disease progression, and survival. To date, breast cancer studies show large variation in reported insomnia prevalence rates, and the severity of sleep complaints in these patients have been difficult to assess. Thus, these issues require further investigation using standardised and validated measures.

In this observational study, we aim to investigate the prevalence and severity of insomnia in a cohort of breast cancer patients at the Christie Hospital using the Insomnia Severity Index (ISI), a validated measure for insomnia. This study will consist of two stages. In Stage 1, patients aged 18 and over, who provide informed consent and have a diagnosis of Stage I, II or III breast cancer in the previous 12 months will be asked to complete the validated ISI. Using the ISI, participants identified as having sleeping difficulties and/or insomnia will be invited to Stage 2 of the study. In this stage, participants will be asked to track their sleep each morning for 3 weeks using a digital sleep diary downloaded onto their own smartphone. They will also be asked to complete a series of questionnaires gathering information regarding their quality of life, well-being, and health. This research will provide a better understanding of sleeping patterns, sleeping difficulties and insomnia in patients with breast cancer, and in the long-term, help us design better treatments for patients with sleeping problems.
Trial Id: Identification of New Prognostic Markers for Breast Cancer. Recruitment Status: Recruiting Trail description: Candidate markers have been identified thanks to an original approach developed by our research team aiming at detecting ectopic gene expression using public pan-genomic breast cancer data. The same approach had already been used and validated in lung tumors, leukemias and lymphomas. The main objective of the present research is to use tumor samples from patients in a retrospective and prospective cohort to test and validate the relevance of these prognostic markers in breast cancer. Inclusion Criteria: Adult female patients with breast cancer Exclusion Criteria: Presence of another cancer, excluding basal cell cancers or pre-neoplastic lesions of the cervix.
Subject under guardianship or subject deprived of liberty
Impossibility of collecting information on exposure (subjects recently arrived in France, foreign language, etc.)
Male patients
Provide description for trial id: NCT03436069  
 Candidate markers have been identified thanks to an original approach developed by our research team aiming at detecting ectopic gene expression using public pan-genomic breast cancer data. The same approach had already been used and validated in lung tumors, leukemias and lymphomas. The main objective of the present research is to use tumor samples from patients in a retrospective and prospective cohort to test and validate the relevance of these prognostic markers in breast cancer.
Trial Id: Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer Recruitment Status: Unknown status Trail description: In this study we aim to:

Assess serum miRNA-373, miRNA-425-5p expression in patients with breast cancer.
Explore their correlations with breast cancer clinicopathological documented data including staging, grading and tumor receptors. Inclusion Criteria: Female age 20 years or older
documented diagnosis of breast cancer based on physical examination, imaging and histopathology
possibility of obtaining blood samples from the subject. Exclusion Criteria: All patients with prior history of exposure to chemotherapy, radiotherapy or hormonal therapy .
patients with other malignancies.
patients with chronic inflammatory diseases.
patients with missed documentation for histopathological diagnosis of breast cancer.
Trial Id: What Matters Most: Choosing the Right Breast Cancer Surgery for You Recruitment Status: Completed Trail description: What Matters Most is a study that aims to determine how best to help women of lower socioeconomic status make high-quality decisions about early stage breast cancer treatments. What Matters Most will be comparing two decision aids used in the clinic visit to usual care (what normally happens in the clinic). The first decision aid (Option Grid) presents evidence-based information about lumpectomy and mastectomy in a tabular format using text only. The second decision aid (Picture Option Grid) presents evidence-based information about lumpectomy and mastectomy using pictures, pictographs and simplified text. What Matters Most aims to show that the interventions can reduce disparities in decision-making and treatment choice between women of high and low SES. Inclusion Criteria: Assigned female at birth;
18 years and older;
Confirmed diagnosis (via biopsy) of early stage breast cancer (stages I-IIIA);
Eligible for both breast-conserving surgery and mastectomy based on medical records and clinician's opinion before surgery;
Spoken English, Spanish, or Mandarin Chinese. Exclusion Criteria: Transgender men and women;
Women who have undergone prophylactic mastectomy;
Women with visual impairment;
Women with a diagnosis of severe mental illness or severe dementia;
Women with inflammatory breast carcinoma.
Provide description for trial id: NCT03136367  
 What Matters Most is a study that aims to determine how best to help women of lower socioeconomic status make high-quality decisions about early stage breast cancer treatments. What Matters Most will be comparing two decision aids used in the clinic visit to usual care (what normally happens in the clinic). The first decision aid (Option Grid) presents evidence-based information about lumpectomy and mastectomy in a tabular format using text only. The second decision aid (Picture Option Grid) presents evidence-based information about lumpectomy and mastectomy using pictures, pictographs and simplified text. What Matters Most aims to show that the interventions can reduce disparities in decision-making and treatment choice between women of high and low SES.
Trial Id: Comparison of Ultrasound and Breast MRI for Breast Cancer Detection Recruitment Status: Recruiting Trail description: The goal of this randomized clinical trial is to compare diagnostic results of secondary breast cancer surveillance using breast ultrasound abbreviated MRI and full protocol MRI. Inclusion Criteria: Women aged 20-75 with a history of breast cancer (in situ carcinoma or invasive breast cancer [stage 0-3])
Women with a negative resection margin in the pathology results of the last surgical specimen from past breast cancer
Women with dense breasts with pattern C (heterogeneously dense) or D (extremely dense breasts) using AI-based Lunit INSIGHT for Mammography (version 1.1.4.3, Lunit Inc.) in the most recent mammography
Women who have not had a breast imaging test within 6 months
Women who agreed to undergo regular annual mammography, breast ultrasound, and breast MRI
If mammography, ultrasound, or breast MRI was performed within the last 1 year, the most recent test result is normal or positive (BI-RADS 1 or 2) Exclusion Criteria: Patients with symptoms related to current breast cancer or breast cancer recurrence (palpable mass, bloody or transparent nipple secretion, palpable mass in the axillary region, abnormal skin changes in the breast or nipple)
If you have been diagnosed with regional recurrence (axillary lymph nodes, supraclavicular and subclavian lymph nodes, internal mammary lymph nodes, etc.) or distant metastases
In case of bilateral total mastectomy
If women are receiving chemotherapy for cancer in other organs
Women during pregnancy or lactation
Glomerular filtration rate < 30 mL/min/1.73m2, or patients with renal insufficiency on dialysis
If women have severe claustrophobia
If women have a metal prosthesis that is not suitable for MR (e.g. breast tissue expander, etc.)
If there is a history of severe contrast agent side effects (e.g., anaphylactoid reaction, dyspnea, etc.)
Provide inclusion criteria for trial id: NCT05797545  
 Women aged 20-75 with a history of breast cancer (in situ carcinoma or invasive breast cancer [stage 0-3])
Women with a negative resection margin in the pathology results of the last surgical specimen from past breast cancer
Women with dense breasts with pattern C (heterogeneously dense) or D (extremely dense breasts) using AI-based Lunit INSIGHT for Mammography (version 1.1.4.3, Lunit Inc.) in the most recent mammography
Women who have not had a breast imaging test within 6 months
Women who agreed to undergo regular annual mammography, breast ultrasound, and breast MRI
If mammography, ultrasound, or breast MRI was performed within the last 1 year, the most recent test result is normal or positive (BI-RADS 1 or 2)
Provide exclusion criteria for trial id: NCT05797545  
 Patients with symptoms related to current breast cancer or breast cancer recurrence (palpable mass, bloody or transparent nipple secretion, palpable mass in the axillary region, abnormal skin changes in the breast or nipple)
If you have been diagnosed with regional recurrence (axillary lymph nodes, supraclavicular and subclavian lymph nodes, internal mammary lymph nodes, etc.) or distant metastases
In case of bilateral total mastectomy
If women are receiving chemotherapy for cancer in other organs
Women during pregnancy or lactation
Glomerular filtration rate < 30 mL/min/1.73m2, or patients with renal insufficiency on dialysis
If women have severe claustrophobia
If women have a metal prosthesis that is not suitable for MR (e.g. breast tissue expander, etc.)
If there is a history of severe contrast agent side effects (e.g., anaphylactoid reaction, dyspnea, etc.)